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Abstract
The current study aimed to examine the potential effects of CBD isolate for alleviating
menstrual-related symptoms (MRS). Participants (N = 33, MAGE = 20.50, MBMI = 23.02)
were assigned randomly to two open-label dosing groups (160mg, n = 17; 320mg, n = 16)
and completed monthly surveys for four months that included MRS-related measures. We
examined differences in MRS and related outcomes between baseline and three months
of CBD administration. Results revealed reductions in MRS, irritability, anxiety, global
impression, stress, and subjective severity scores with a small effect when comparing
baseline to all three months of CBD administration. Findings suggest that CBD may have
potential for treating MRS. Further research is warranted examining the potential to
optimize CBD administration for reducing MRS (i.e., terpenes, routes of administration,
time of administration).

Keywords: menstruation, menstrual-related symptoms, cannabidiol, intervention,
treatment
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The Effects of Cannabidiol Isolate on Menstrual-related Symptoms
Menstrual-Related Symptoms
Most menstruating individuals experience some form of discomfort or dysphoria
in the days or weeks before menstruation (Yonkers et al., 2008). Approximately 75% of
those who menstruate experience unpleasant menstrual-related symptoms (MRS; Wakil
et al., 2012). MRS, including but not limited to premenstrual syndrome (PMS)
symptoms, are characterized by both physical (e.g., cramps, headache, breast tenderness)
and psychological (e.g., irritability, tension, depressed mood) experiences (Yonkers et al.,
2008). Findings from prospective and retrospective studies suggest that 5-8% of
individuals who experience menstrual cycles have moderate to severe symptoms (though
some studies suggest this is an underestimation— e.g., Direkvand-Moghadam et al.,
2014; Halbreich et al., 2003) and up to 20% of fertile-aged individuals have clinically
relevant premenstrual complaints (Borenstein et al., 2003).
The menstrual cycle (MC) occurs in five phases: menstrual (days one-five),
follicular (days six-12), ovulatory (days 13-16), luteal (day 17 to the premenstrual phase),
and premenstrual (five days prior to menstrual bleeding; Evans et al., 1998; Johannes et
al., 1995; Pastor & Evans, 2003); MRS are most often experienced in the menstrual and
premenstrual phases. Premenstrual symptoms, a sub-set of MRS that present in
approximately 20-40% of reproductive aged individuals (Mischell, 2005), often occur
cyclically beginning in the luteal phase and subside quickly after menstruation onset
(Strine et al., 2005). Symptom expression among individuals varies between a few days
and two weeks; symptoms often worsen approximately 6 days before and peak at 2 days
prior to menstruation (Pearlstein et al., 2005; Meaden et al., 2005). Individuals who
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experience severe PMS symptoms that include at least one disabling affective symptom
(e.g., affective lability, irritability, anxiety) might be diagnosed with premenstrual
dysphoric disorder (PMDD), which occurs in approximately 3-9% (24 to 72 million) of
menstruating individuals (Halbreich et al., 2003). PMDD is the psychologically
dominated form of PMS, characterized by depressed mood, anxiety, irritability, anger,
and insomnia all attributable to the menstrual cycle (Halbreich et al., 2003; Indusekhar et
al., 2007). Despite the widespread impact of PMDD and PMS, up to 89% of those who
likely suffer from PMDD may go undiagnosed (Halbreich et al., 2003) and it is estimated
that less than half of those with severe PMS seek medical support or intervention (Hylan
et al., 1999). Because MRS are often conflated with other medical conditions and
disorders (e.g., pain, depression), PMS and PMDD are difficult to identify and diagnose.
Some individuals may experience psychological symptoms as a result of disabling
physical symptoms (and/or vice versa) making diagnosis even more challenging.
Though MRS are often mild, they can be severe enough to disrupt daily life; one
in 3 menstruating individuals halt typical daily activities because of menstrual symptoms
(Shoep et al., 2019). Moderate to severe MRS can be psychologically and physically
disabling in areas ranging from family and personal relationships to work productivity
and social activities (Freeman, 2005). Individuals with severe MRS may experience
symptoms for up to 2,800 days (~7.7 years) across their reproductive age span, which can
have a substantial impact on various domains of their lives (Halbreich et al., 2003). Some
consequences of MRS include absenteeism, lost wages, lowered productivity, adverse
effects on relationships, and diminished quality of life (Borenstein et al., 2003;
Borenstein et al., 2007).
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MRS and Clinical Relevance
The presence of MRS have been studied extensively; however, more clinical
research is necessary, not only because of its impact on everyday life, relationships, and
economic losses (Halbreich et al., 2003), but also because of the association between
MRS and psychiatric symptomatology and diagnosis (Gonda et al., 2008). Though
symptoms vary considerably across individuals (Steiner & Born, 2000), the collective
impact of psychological distress from MRS may pose important public health
implications. Strine and colleagues (2005) found that individuals who experience MRS
are 1.7 to 3.0 times more likely to report insomnia or sleepiness, recurrent pain, sadness,
nervousness, restlessness, hopelessness, worthlessness, and that everything was “an
effort”; these symptoms often resulted in impaired quality of life and inability to maintain
engagement in everyday activities (Strine et al., 2005). Additionally, behavioral
responses during menstruation, such as reduced social engagement, may also contribute
to feelings of isolation and depression (van Iersel et al., 2016).
Ovarian hormonal changes that occur during the premenstrual phase of the
menstrual cycle may establish a neuro-modulatory influence that contributes to the onset
and maintenance of maladaptive or clinical anxiety among those who menstruate (Nillni
et al., 2011). These hormonal changes that occur throughout the menstrual cycle are
associated with changes in affect and increases in symptoms that are associated with a
multitude of mental health conditions (Brier et al., 1986; Freeman et al., 2003; Gonda et
al., 2008; Kaspi et al., 1994; Kornstein et al., 2008). The association between hormonal
influence and mental health outcomes is also consistent with findings that show treatment
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through ovarian suppression with leuprolide reduced symptoms among those with
premenstrual syndrome (Schmidt et al., 1998).
More specifically, the premenstrual phase is associated with exacerbations of
mood and anxiety disorders such as major depression (Kornstein et al., 2008), panic
disorder (Breier et al., 1986; Cook et al., 1990; Kaspi et al., 1994), and bipolar disorder
(e.g., Rasgon et al., 2003). Typically, symptoms that characterize these disorders
intensify during the late luteal phase, when progesterone and estradiol are declining, and
during the early follicular phase, when levels of progesterone and estradiol are both at
their lowest levels (Hendrick et al., 1996). Those who experience PMS have a higher
prevalence of major depressive disorder (MDD) and anxiety disorders and greater risk of
subsequent development of incidental affective disorders than do individuals without
PMS (Rubinow et al., 1998). Other disorders that are associated with certain phases of
the menstrual cycle include eating disorders (e.g., Lester et al., 2003) and substance use
disorders (e.g., Allen, 1996; Evans et al., 2002). Additionally, findings have suggested an
association between the premenstrual phase and psychiatric admissions (Jang &
Elfenbein, 2019) and that individuals may be at greater risk of suicide attempts and
completed suicides during the menstrual phase (Saunders & Hawton, 2006).
Currently Available Treatments
Though MRS are prevalent and, often, debilitating, effective remedies for
managing symptoms are scarce. Managing symptoms associated with menstruation is
complex given the variability in symptoms across individuals who menstruate. As a
result, management of MRS is often frustrating for both patients and health-care
providers (Dickerson et al., 2003). Existing interventions range from lifestyle
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modifications to hormonal treatments and prescription medications that aim to alleviate
symptoms and reduce their impact on everyday activities (Dickerson et al., 2003). Those
with mild symptoms might effectively manage symptoms through lifestyle changes,
including healthy diet, sodium and caffeine restriction, exercise, and stress reduction
(Dickerson et al., 2003) or through of use over-the-counter (OTC) pain medications
(OTC; ibuprofen, naproxen) or behavioral remedies (e.g., heating pad). For individuals
who experience more severe symptoms, lifestyle changes and OTC medications are often
ineffective (Dickerson et al., 2003).
Most available intervention strategies that have been shown efficacious in treating
MRS have largely focused on physical symptoms. There is a relative lack of clinical
research (and potential intervention strategies) aimed at improving psychological MRS.
Clinically meaningful PMS or PMDD, which is primarily characterized by psychological
symptoms, are most often treated with pharmacotherapy (e.g., Selective Serotonin
Reuptake Inhibitor; SSRI) or hormonal interventions (e.g., birth control); however, these
interventions have only shown clinically meaningful improvement in approximately 60%
of those who engage with the interventions (Pearlstein and Steiner, 2008). Though SSRIs
have shown some improvement in treating MRS, side effects often occur with SSRI use.
Common side effects of SSRIs include insomnia, drowsiness, fatigue, nausea,
nervousness, headache, mild tremor, and sexual dysfunction (ACOG, 2000; Dimmock et
al., 2000).
Hormonal strategies have also been used to treat PMS and PMDD; these
interventions include long-acting gonadotropin-releasing hormone (GnRH) agonists, such
as leuprolide, and combined oral contraceptives (COCs; i.e., birth control pill), or other
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hormonal birth control methods. Leuprolide and birth control methods may be effective
in alleviating symptoms (affective lability, anxiety), but there are also a multitude of side
effects from these treatments. Leuprolide, which functionally results in medical
menopause, is associated with side effects including hot flashes, night sweats, and
vaginal dryness (Wyatt et al., 2004), and potentially puts individuals at risk for
osteoporosis (Cunningham et al., 2009). Birth control has been found to induce or worsen
feelings of dysphoria (Bhatia & Bhatia, 2002) and is associated with a greater likelihood
of adverse mood symptoms (Jungheim et al. 2009). Birth control is also implicated with
increased risk of endometrial cancer, coronary heart disease, breast cancer, stroke, and
pulmonary embolism (Rossouw et al. 2002).
Though there are treatments to alleviate specific acute symptoms (e.g., cramps,
headaches, breast sensitivity), there are no effective treatments to date that target physical
and psychological symptoms simultaneously and that do not introduce side effects and/or
increase medically-relevant risk factors. Given the lack of adequate treatments to
alleviate symptoms, many individuals self-medicate. Self-medication theory (SMT)
suggests that individuals experiencing periods of greater negative affect or physical
symptoms may use substances to cope with those experiences (Khantzian, 1997; Joyce et
al., 2019). Indeed, findings have consistently supported that those who experience PMS
are more likely to drink alcohol in effort to cope with symptoms, more specifically,
negative mood (Carroll et al., 2015; Epstein et al., 2006; Strine et al., 2005). Prior
research has also suggested that nicotine use increases during the premenstrual phase of
the menstrual cycle (Joyce et al., 2019).
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Recent literature also suggests that some individuals attempt to alleviate MRS by
using cannabis and report having expectations that cannabis can improve MRS (Hanzal et
al., 2019; Slavin et al., 2017). Slavin and colleagues (2017) found that individuals
reported expectancies that cannabis would alleviate all symptoms associated with
PMS/PMDD except for overeating/food cravings. Specifically, participants reported that
they believed cannabis would help treat irritability, labile affect, depressive moods,
anxiety, and sleep disturbances more so than physical symptoms including breast
tenderness and bloating (Slavin et al., 2017). Consistent with SMT, individuals with
expectancies related to positive MRS outcomes associated with cannabis use also
reported greater MRS and greater monthly cannabis use (Slavin et al., 2017).
A recent study examined whether increases in depressed mood and coping
motives would predict increased pre-menstrual and menstrual cannabis use among
naturally cycling cannabis users with and without retrospectively identified PMDD (via
structured clinical interview) and prospectively identified PMDD (via elevated premenstrual depressed mood; N = 69; Mage = 29.25, SDage = 5.66). Joyce and colleagues
(2021) employed electronic daily diary methods and validated menstrual phase by using
salivary progesterone concentrations across 32 days. Findings showed that coping
motives were associated with heightened pre-menstrual and menstrual phase cannabis use
in those with retrospectively identified PMDD and depressed mood was associated with
increased menstrual-phase cannabis use in those with retrospectively/prospectively
identified PMDD. Further, prospectively identified PMDD meaningfully moderated the
relation between depressed mood and menstrual-phase cannabis use quantity. In those
with prospectively identified PMDD, positive mood and enhancement motives were
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associated with decreased cannabis use during the follicular/ovulatory phases. Individuals
with retrospectively identified PMDD also displayed greater overall cannabis use
quantity (measured by number of standard joints; M = 3.44, SD = 2.84) compared to
individuals without retrospectively identified PMDD (M = 1.85, SD = 1.82; p = 0.008;
Joyce et al., 2021).
Given the prevalence and salience of MRS and the relative paucity of remedy
options for the whole range of symptoms, consideration of novel intervention strategies is
warranted. One intervention strategy with potential to impact a wide range of symptoms
that overlap with MRS (including irritability, depressive moods, anxiety, pain, and sleep
disturbances) is cannabis use, specifically cannabidiol (CBD; Russo et al. 2007; Russo &
Hohmann 2013; Slavin et al., 2017).
Cannabis and MRS
Cannabis has been shown to have therapeutic effects on physical (Reiman et al.,
2017) and psychological (Solowij et al., 2018) experiences. Phytocannabinoids
(cannabinoids that occur naturally in the cannabis plant) found in cannabis work on the
endocannabinoid system, which consists of a series of neuromodulatory lipids and
receptors located throughout the central and peripheral nervous systems that accept
endogenous cannabinoids (anandamide, 2-arachidonoylglycerol) and phytocannabinoids.
The two most abundant (in the plant) and well-researched phytocannabinoids are delta-9
tetrahydrocannabinol (THC) and cannabidiol (CBD; Babson et al., 2017; Haney, 2022).
Recent literature has examined the potential health benefits of non-intoxicating or
minimally psychoactive extracts and constituents of the cannabis plant (Lopez et al.,
2020). Though THC has high-inducing effects, in which users often feel euphoric, CBD
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does not elicit the same high-inducing or impairing effects that are observed with THC
(Maroon and Bost, 2018). Hemp-derived CBD (cannabis with less than 0.3% THC
content by dry weight) can be consumed as whole plant or as a CBD isolate; whole-plant
hemp-derived CBD includes a complex phytochemical matrix from the plant while CBD
isolate has no other cannabinoid constituents present (Marinotti & Sarill, 2020). In
addition to whole-plant and isolate, researchers and pharmaceutical companies can
develop targeted formulations of CBD combined with terpenes and/or flavonoids in effort
to achieve specific outcomes (e.g., improved anxiety versus improved sleep).
CBD (whole plant, isolate, and targeted formulations) has been demonstrated to
yield a range of possible therapeutic effects (Schier et al., 2012); more specifically, CBD
has demonstrated various beneficial health outcomes such as mood regulating,
neuroprotective, analgesic, anti-inflammatory, anxiolytic, and immunomodulatory effects
(Schultes 1969; Campos et al. 2016; Hillard 2000). Chronic pain is one of the most often
cited reasons that patients are accessing medicinal cannabis in states where it is available
(Sexton et al., 2016). More specifically, approximately 36% of medical cannabis users
reported using cannabis for headaches or migraines; these users reported an average 3.6point decrease (on a 10-point scale) in headache severity after cannabis use (Sexton et al.,
2016). Although the effectiveness of CBD- isolate for pain management has not been
well assessed clinically, nabiximols (cannabis extract containing THC and CBD) have
shown promising results in symptomatic pain management (Boyaji et al., 2020; Überall,
2020). An analysis including seven trials of nabiximols, and one trial of smoked wholeplant cannabis demonstrated that the plant-derived cannabinoids were 40% more likely to
reduce pain than the placebo (Andreae et al., 2015).
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CBD has also shown anxiolytic effects in both animal and human studies (Zuardi
et al., 1993; Zuardi et al., 2006). Zhornitsky and Potvin (2012) suggest that high-doses of
CBD (150-600mg/daily) may decrease anxiety and increase mental sedation in healthy
individuals; clinical trials have demonstrated that high-dose CBD may be useful for the
treatment of social anxiety disorder as well as insomnia. CBD’s anxiolytic effects are
similar to those of approved drugs to treat anxiety (Resstel et al., 2009). In a clinical trial
with individuals diagnosed with social anxiety disorder, each participant received either a
single dose of 600 mg of CBD or a placebo before completing a simulated public
speaking test; CBD was associated with a greater decrease in anxiety compared to the
placebo group (Bergamaschi et al., 2011).
The endocannabinoid system has also been implicated for its role in sleep, and
more specifically, the effects that cannabis may have on sleep latency (Jang & Elfenbein,
2019). Clinical evidence has demonstrated that both adults and adolescents may use
cannabis to cope with sleep disturbances (Babson & Bonn-Miller, 2014). Varying doses
of CBD have been shown to have differential effects on wakefulness; low-doses of CBD
have demonstrated a stimulating effect, while high-doses have shown a sedating effect
(Babson et al., 2017). In a study among individuals with insomnia, findings showed that
ingestion of 160mg daily of CBD increased total sleep time and decreased the frequency
of arousals during the night (Carlini & Cuhna, 1981).
Another notable benefit of cannabis as a form of treatment is safety (Shannon et
al., 2019) compared to other currently available treatments for MRS that have the
potential for abuse, overdose, and adverse side effects (e.g., OTC pain medications,
SSRIs; Reiman et al., 2017). According to exhaustive reviews, both healthy individuals
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and clinical patients with different conditions did not experience significant adverse
effects to acute or chronic administration of CBD by various routes (Bergamaschi et al.,
2011; Iffland & Grotenhermen, 2017).
Although CBD has been shown to have a range of health benefits, there is a
relative dearth of human clinical data on its potential to affect a variety of health
outcomes (Lopez et al., 2020). Given the considerable overlap in symptoms impacted
positively by CBD and MRS (e.g., anxiety, sleep disturbance, migraine) and the relative
lack of side-effects associated with CBD, it is reasonable to consider that CBD may be a
viable option for MRS intervention (Baron, 2018; Carlini & Cunha, 1981; Shannon et al.,
2019).
Current Study
Although research has suggested cannabis as a potential alternative treatment for
MRS that has fewer side effects compared to currently available treatments
(Grotenhermen & Russo, 2002; Slavin et al., 2017), further research is needed to examine
its efficacy. The current study aims to examine the potential effects of orally ingested
CBD isolate soft-gels on physical and/or psychological MRS. Researchers assigned
randomly participants to consume 160mg or 320mg doses of hemp-derived pure CBD
isolate (containing no other cannabinoids or cannabinoid-related constituents) to be taken
daily for five consecutive days each month beginning the first day that MRS symptoms
are experienced. Primary health outcomes of interest include MRS, anxiety, stress, sleep
quality, and mood, as well as exploratory health outcomes including alcohol use,
depression, and irritability.
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Methods
Participants
Participants included (N = 33; MAGE = 20.50, SDAGE = 2.63; MBMI = 23.02, SDBMI
= 2.68) individuals who self-reported experiencing a normal menstrual period (occurring
every 21-38 days and lasting between 4-8 days; Creinin et al., 2004), were willing to
track their menstrual cycle systematically, and experienced moderate-to-severe MRS or
are diagnosed currently with PMDD (MMRSQ = 54.85, SDMRSQ = 12.02, range = 34-87;
Diagnosed with PMDD = 0). Individuals who self-reported using cannabis or cannabiscontaining product within 30 days of screening, trying to get pregnant, having a past
suicide attempt or current suicidal plan in the past year, having a BMI of underweight
(18kg/m2 and below) or obese (30kg/m2 and above), or having a DSM-5 diagnosis (e.g.,
current psychotic disorder) or significant disease or disorder (e.g., epilepsy) that would
interfere with the study treatment were excluded from the study.
Materials
Screener Measures
Demographics. Demographics consisted of a series of questions regarding age,
ethnicity, and questions related to menstrual symptom experience (e.g., birth control
usage, menstrual-related health conditions).
Eligibility Questionnaire. A checklist of eligibility criteria included Yes/No
statements that participants endorsed or denied.
Menstrual-Related Symptom Questionnaire. The Menstrual-Related Symptom
Questionnaire is a 26-item measure adapted from the Menstrual-Symptom Questionnaire
(Chesney & Tasto, 1975) containing common physiological and psychological symptoms
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that individuals may experience because of their menstrual cycle (Ferretti et al., in press).
Respondents report the severity in which they experience each symptom on a four-point
Likert scale (1 = none to 4 = severe). Scores can range from 26 to 104. Internal
consistency for this sample is good (Cronbach’s α range = 0.77 - 0.89).
Brief Irritability Test (BITe). The BITe is a 5-item self-report measure to
evaluate irritability symptoms over the past two weeks (Holtzman et al., 2015). Each
item is measured on a six-point Likert scale (1 = never to 6 = always). A higher total
score indicates greater irritability, and scores can range from 5 to 30. All five items
displayed minimal conceptual overlap with related constructs (e.g., depression, anger;
Holtzman et al., 2015). Internal consistency for this sample is good (Cronbach’s α range
= 0.83 - 0.90).
Drug Abuse Screening Test (DAST). The DAST is a 28-item self-report
measure used to provide a brief clinical screening for examining the extent of drug use
involvement. Questions are provided in Yes/No format. A score of 1 on each item
response indicates drug use while a score of 0 does not. The internal consistency
reliability estimate was a .92, and a factor analysis of item intercorrelations suggested a
unidimensional scale (Skinner, 1982). Using a cutoff score of 6 has been found to provide
excellent sensitivity for identifying patients with substance use disorders. Internal
consistency for this sample is sub-optimal (Cronbach’s α = 0.61).
Alcohol Use Disorders Identification Test (AUDIT). The AUDIT is a 10-item
screening tool to evaluate for alcohol consumption, drinking-behaviors, and alcoholrelated problems (Saunders et al., 1993). A score of ‘8’ or more is characterized as
hazardous or harmful alcohol use. Item responses range are measured on a Likert scale (0
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= never to 4 = daily or almost daily), and scores can range from 0 to 40. Internal
consistency for this sample is acceptable (Cronbach’s α range = 0.68 - 0.83).
Depression, Anxiety, and Stress Scale-21 (DASS-21). The DASS-21 is a 21item self-report instrument used for measuring depression, anxiety, and tension/stress in
the past week. Item Responses are measured on a four-point Likert scale (0 = did not
apply to me at all to 3 = applied to me very much or most of the time). Higher scores
indicate higher severity levels of depression, anxiety, and stress; scores can range from 0
to 42. The DASS-21 is a useful tool for screening both clinical and subclinical threshold
levels of these emotional states (Lovibond & Lovibond, 1995). Internal consistency for
this sample is good (Cronbach’s α range = 0.80 - 0.93).
Pittsburgh Sleep Quality Index (PSQI). The PSQI is a 9-item questionnaire that
provides an index of sleep quality through a one-month interval of time. Participants
answer open-ended questions that are scored based on categories and questions on a 4point Likert-scale (0 = very good to 3 = very bad). Sleep pattern indices can be calculated
separately or summed to provide a global sleep quality score. Global scores range from 0
to 21 with higher scores indicating worse sleep quality (Buysse et al., 1989). The PSQI is
a psychometrically sound measure for use across a variety of clinical and non-clinical
populations (Buysse et al., 1989).
Premenstrual Dysphoric Disorder (PMDD) DSM-5 Criteria. Diagnostic
criteria for individuals with PMDD are found in the Diagnostic and Statistical Manual of
Mental Disorders – Fifth Edition (DSM-5; American Psychiatric Association, 2013).
Individuals endorsed or denied 11 symptoms that are included in the criteria of PMDD.
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Columbia Suicide Severity Rating Scale (CSSRS) 4-5. The CSSR is a measure
used to assess suicidal risk. The current study only included item 4 "Have you thought
about a method of killing yourself but do not intend to act on it" and item 5 "Have you
started to work out or worked out details of how to kill yourself? Do you intend to carry
out this plan?"
Monthly Survey Measures
Visual Analogue Mood Scale (VAMS). We included one item of the 16-item
VAMS. Participants are asked to indicate a point on a straight line placed between two
words that describe opposite mood states (happy/positive or sad/negative for this study;
Luria, 1975). The VAMS is considered a valid measure and high test-retest reliability
was demonstrated both across and within patients (Luria, 1975).
Global Impression of Change. A 7-point scale was used to capture participants’
beliefs about the global improvement of their MRS since enrolling in the study.
Menstrual Demographics. Menstrual demographics consisted of questions
related to menstrual symptom experience (e.g., birth control usage, menstrual cycle
tracking).
Menstrual-Related Symptoms Questionnaire. See description above.
Depression, Anxiety, and Stress Scale-21 (DASS-21). See description above.
Brief Irritability Test (BITe). See description above.
Pittsburgh Sleep Quality Index (PSQI). See description above.
Alcohol Use Disorders Identification Test (AUDIT). See description above.
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Drug
CBD Isolate. CBD isolate (extracted and purified from whole-plant hemp) was
used for this study in effort to isolate the effects of CBD in the absence of other cannabis
plant constituents. CBD isolate was provided in the form of 20mg soft-gel capsules. The
CBD was suspended in MCT (medium-chain triglycerides) oil to promote bioavailability
of CBD.
Procedures
Potential participants were contacted via bulk email and asked to complete an
electronic screener to determine study eligibility through QuestionPro. If at any point
during the screener individuals endorsed a question that would exclude them from the
study, then the survey truncated. Those who meet inclusion criteria were contacted and
invited to join the study. Individuals that were interested in enrolling were assigned
randomly to one of 2 open-label study groups (160mg, n = 17; 320mg, n = 16) and
attended a virtual screening session that included informed consent procedures via Zoom.
During informed consent, a research assistant re-screened for eligibility criteria. All
participants met criteria at this time.
Participants completed monthly electronic surveys related to MRS for one
baseline month. If participants provided at least 80% of requested data for the baseline
month, they were provided with a 3-month supply of CBD isolate. Participants were
asked to continue completing the monthly surveys related to MRS throughout the 3month period during which they took the provided CBD. Starting the first day that
participants believed they were experiencing symptoms each month, they began taking
their assigned dose daily for five consecutive days.
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Data Analysis Plan
Data were analyzed using SPSS (Version 28.0). Descriptive statistics were used to
characterize participants’ age, race, birth control use, diagnoses that impact the MC (i.e.,
PMDD), menstrual tracking, and health outcomes throughout the study (see Tables 3, 4).
Descriptive statistics were used to summarize health outcomes in the screener and
bivariate correlations were conducted to examine relations between study outcomes
throughout the study (see Tables 1, 2). All internal consistency data are presented as
ranges to reflect internal consistency for all time points for which we administered the
measures.
Researchers examined whether various health outcomes differed from baseline to
the three different intervention months and between dosing conditions. A series of mixed
2x4 ANOVAs were conducted to examine potential changes in all health-related
outcomes from baseline to months one, two, and three of CBD administration between
dosing conditions (160mg and 320mg).
Results
Screener Analyses
Descriptive statistics are presented in various tables (see Tables 1, 3, 4, 5). A
series of correlations were conducted to examine relations between study outcome
variables (see Table 2).
Monthly Analyses
We conducted a series of mixed 2 (condition) x 4 (month) ANOVAs to examine
potential changes in health-related outcomes from baseline to all three months of CBD
administration between dosing groups (160mg and 320mg).
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MRS
A 2x4 mixed ANOVA revealed a meaningful main effect of time on MRSQ
scores (Greenhouse-Geisser Adjusted; F(2.43, 75.39) = 17.42, p <.001, ηp2 = 0.36,
observed power = 1.00). Regardless of dosing condition, participants yielded
meaningfully higher baseline MRSQ scores (M = 51.51, SD = 1.78) compared to months
one (M = 45.04, SD = 1.46), two (M = 41.03, SD = 1.04), and three (M = 41.87, SD =
1.24) of CBD administration. Findings revealed no meaningful interaction effect between
dosing condition and time (Greenhouse-Geisser Adjusted; F(2.43, 75.39) = 0.83, p =
0.48, ηp2 = 0.03, observed power = 0.20) or main effect of dosing condition (F(1, 31) =
.01, p = 0.92, ηp2 = 0.00, observed power = .05) on MRSQ scores.
A 2x4 mixed ANOVA revealed a meaningful main effect of time on physiological
MRSQ scores (Greenhouse-Geisser Adjusted; F(2.15, 66.66) = 11.66, p <.001, η p2 = 0.27,
observed power =1.00). Participants yielded meaningfully higher baseline physiological
MRSQ scores (M = 25.79, SD = 1.03) compared to months one (M = 22.87, SD = 0.67),
two (M = 21.24, SD = 0.67), and three (M = 21.53, SD = 0.63) of CBD administration.
Findings revealed no meaningful interaction effect between dosing condition and time
(Greenhouse-Geisser Adjusted; F(2.15, 66.66) = 0.15, p = 0.87, ηp2 = 0.10, observed
power = 0.07) or main effect of dosing condition (F(1, 31) = .02, p = 0.92, η p2 = 0.02,
observed power = 0.13) on physiological MRSQ scores.
A 2x4 mixed ANOVA revealed a meaningful main effect of time on
psychological MRSQ scores (F(3, 93) = 12.13, p <.001, η p2 = 0.28, observed power
=1.00). Participants yielded meaningfully higher baseline psychological MRSQ scores
(M = 20.97, SD = 0.85) compared to months one (M = 18.48, SD = 0.94), two (M =
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16.11, SD = 0.49), and three (M = 16.67, SD = 0.73) of CBD administration. Findings
revealed no meaningful interaction effect between dosing condition and time (F(3, 93) =
1.68, p = 0.18, ηp2 = 0.05, observed power = 0.43) or main effect of dosing condition
(F(1, 31) = 1.46, p = 0.24, ηp2 = 0.05, observed power = 0.22) on psychological MRSQ
scores.
A 2x4 mixed ANOVA revealed a meaningful main effect of time on appetite
MRSQ scores (F(3, 93) = 11.51, p < .01, η p2 = 0.27, observed power = 0.91). Participants
yielded meaningfully higher baseline appetite MRSQ scores (M = 4.75, SD = 0.30)
compared to months one (M = 3.69, SD = 0.23), two (M = 3.70, SD = 0.22), and three (M
= 3.67, SD = 0.22) of CBD administration. Findings revealed no meaningful interaction
effect between dosing condition and time (F(3, 93) = 1.39, p = 0.25, η p2 = 0.04, observed
power = 0.36) or main effect of dosing condition (F(1, 31) = .24, p = 0.63, ηp2 = 0.01,
observed power = .08) on appetite MRSQ scores.
A 2x4 mixed ANOVA revealed a meaningful main effect of time on global
impression of change scores (F(3, 93) = 18.20, p < .001, ηp2 = 0.37, observed power
=1.00). Participants reported meaningful reductions in symptoms using global impression
of change scores when comparing baseline (M = 4.03, SD = 0.03) to months one (M =
3.50, SD = 0.16), two (M = 3.03, SD = .15), and three (M = 3.03, SD = 0.18) of CBD
administration. Findings revealed no meaningful interaction effect between dosing
condition and time (F(3, 93) = 0.38, p = 0.77, η p2 = 0.01, observed power = 0.12) or main
effect of dosing condition (F(1, 31) = .01, p = .69, ηp2 = 0.01, observed power = 0.07) on
global impression of change scores.
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A 2x4 mixed ANOVA revealed a meaningful main effect of time on subjective
severity ratings of MRS (Greenhouse-Geisser Adjusted; F(2.21, 68.51) = 7.50, p < .001,
ηp 2 = 0.20, observed power = 0.95). Participants yielded meaningfully higher baseline
subjective severity ratings of MRS (M = 2.69, SD = 0.10) compared to months one (M =
2.24, SD = 0.12), two (M = 2.15, SD = 0.08), and three (M = 2.09, SD = 0.13) of CBD
administration. Findings revealed no meaningful interaction effect between dosing
condition and time (Greenhouse-Geisser Adjusted; F(2.21, 68.51) = 0.24, p = 0.81, η p2 =
0.01, observed power = 0.09) or main effect of dosing condition (F(1, 31) = 0.94, p =
0.34, ηp 2 = 0.03, observed power = 0.16) on subjective severity ratings of MRS.
Anxiety
A 2x4 mixed ANOVA revealed a meaningful main effect of time on anxiety
scores (F(3, 93) = 3.67, p < .015, ηp2 = 0.11, observed power = 0.79). Participants
reported meaningfully higher baseline anxiety (M = 8.60, SD = 1.19) compared to months
one (M = 5.37, SD = .92), two (M = 6.55, SD = .96), and three (M = 5.96, SD = 1.13) of
CBD administration. Findings revealed no meaningful interaction effect between dosing
condition and time (F(3, 93) = 0.36, p = 0.78, η p2 = 0.01, observed power = 0.12) or main
effect of dosing condition (F(1, 31) = 0.94, p = 0.34, ηp2 = 0.03, observed power = 0.16)
on anxiety scores.
Stress
A 2x4 mixed ANOVA revealed a meaningful main effect of time on stress scores
(Greenhouse-Geisser Adjusted; F(2.44, 75.67) = 4.20, p = 0.02, ηp2 = 0.12, observed
power = 0.78). Participants yielded meaningfully higher baseline stress (M = 12.67, SD =
1.37) compared to months one (M = 10.14, SD = 1.20), two (M = 9.86, SD = 1.16), and
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three (M = 8.61, SD = 1.12) of CBD administration. Findings revealed no meaningful
interaction effect between dosing condition and time (Greenhouse-Geisser Adjusted;
F(2.43, 75.39) = 0.25, p = 0.82, ηp2 = 0.01, observed power = 0.10) or main effect of
dosing condition (F(1, 31) = 0.01, p = 0.93, ηp2 = 0.00, observed power = 0.05) on stress
scores.
Irritability
A 2x4 mixed ANOVA revealed a meaningful main effect of time on irritability
scores (Greenhouse-Geisser Adjusted; F(2.01, 62.15) = 3.22, p = .047, η p2 = .10, observed
power = .60). Participants yielded meaningfully higher baseline irritability (M = 13.52,
SD = .71) compared to months one (M = 11.76, SD = .58), two (M = 11.80, SD = .60),
and three (M = 11.59, SD = .62) of CBD administration. Findings revealed no meaningful
interaction effect between dosing condition and time (Greenhouse-Geisser Adjusted;
F(2.01, 62.15) = 0.61, p = 0.61, ηp2 = 0.02, observed power = 0.17) or main effect of
dosing condition (F(1, 31) = 2.07, p = 0.16, ηp2 = 0.06, observed power = 0.29) on
irritability scores.
Sleep
A 2x4 mixed ANOVA revealed no meaningful interaction effects between dosing
condition and time on global sleep quality scores (F(3, 93) = 0.87, p = 0.46, η p2 = 0.03,
observed power = 0.23) and no meaningful main effects of dosing condition (F(1, 31) =
1.34, p = 0.27, ηp2 = 0.04, observed power = .20) or time (F(3, 93) = 0.98, p = 0.41, ηp2 =
0.03, observed power = 0.26).
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Alcohol Use
A 2x4 mixed ANOVA revealed no meaningful interaction effects between dosing
condition and time on alcohol use (Greenhouse-Geisser Adjusted; F(2.28, 70.70) = 0.34,
p = 0.74, ηp2 = 0.01, observed power = 0.11) and no meaningful main effects of dosing
condition (F(1, 31) = 2.76, p = 0.11, ηp2 = 0.08, observed power = 0.36) or time
(Greenhouse-Geisser Adjusted; F(2.28, 70.70) = 1.16, p = 0.33, η p2 = 0.04, observed
power = 0.26).
Depression
A 2x4 mixed ANOVA revealed no meaningful interaction effects between dosing
condition and time on depression scores (F(3, 93) = 0.13, p = 0.94, η p2 = 0.00, observed
power = 0.07) and no meaningful main effects of dosing condition (F(1, 31) = 0.38, p =
0.54, ηp2 = 0.01, observed power = 0.09) or time (F(3, 93) = 2.27, p = 0.09, η 2p = 0.07,
observed power = 0.56).
VAMS-Mood
A 2x4 mixed ANOVA revealed no meaningful interaction effects between dosing
condition and time on mood scores (F(3, 93) = 2.41, p = 0.07, η p2 = 0.07, observed power
= 0.59) and no meaningful main effects of dosing condition (F(1, 31) = 0.13, p = 0.72, ηp2
= 0.00, observed power = 0.06) or time (F(3, 93) = 0.02, p = 0.99, η 2p = 0.00, observed
power = 0.05).
Discussion
Given that CBD has been demonstrated to yield a range of possible therapeutic
effects on symptoms that overlap with MRS (i.e., anxiety, sleep disturbance, migraine)
and the relative lack of side-effects associated with CBD, it is reasonable to consider that
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CBD may be a viable option for MRS intervention. The current study aimed to examine
the potential effects of orally ingested CBD isolate for alleviating both physical and
psychological MRS. Results revealed meaningful reductions in monthly ratings of MRS
(using the MRSQ), subjective severity of symptoms, global impression of change,
anxiety, irritability, and stress in both conditions when comparing baseline to months
one, two, and three of CBD administration. There were no meaningful reductions (or
other impacts) on monthly ratings of depression, sleep quality, and alcohol use when
comparing baseline to all three months of CBD administration. Taken together, findings
suggest that CBD may have potential for treating MRS and related health outcomes;
further investigation is warranted.
Though past research has suggested cannabis may be a viable option for MRS
intervention (Baron, 2018; Carlini & Cunha, 1981; Shannon et al., 2019), to our
knowledge this study is the first to test the effects of CBD on MRS. Current study
findings are consistent with past research showing the therapeutic effects of CBD on
various experiences associated with MRS. For example, results showed reductions in
monthly ratings of MRS (using the MRSQ, subjective severity, global impression of
change), pain, stress, and anxiety (i.e., Zuardi et al., 2017). Inconsistent with past
research, we found no impact on sleep quality when comparing baseline to all months of
CBD administration. We offer several potential explanations for the current study
outcomes in the context of the extant literature.
MRS was measured using a variety of outcomes, including the MRSQ (which
accounts for physiological and psychological symptoms), subjective severity of MRS
experiences, and global impression of change, which all showed reductions in symptoms
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among both dosing conditions for all months of CBD administration compared to
baseline. Further, we examined distinctive types of symptoms of the MRSQ
(physiological, psychological, appetite), showing reductions in both physiological and
psychological symptoms, which is consistent with past literature documenting effects of
CBD on both experiences (i.e., pain, anxiety; Bergamaschi et al., 2011; Boyaji et al.,
2020; Resstel et al., 2009), as well as appetite-related symptoms. Past research has
documented the therapeutic effects of CBD on pain, and consistent with past research,
findings showed reductions in physiological symptoms, such as headaches; however,
various physiological symptoms that are assessed in the MRSQ have not been examined
in relation to CBD (i.e., abdominal bloating, nausea; Boyaji et al., 2020; Sexton et al.,
2016) and future research is warranted. Though most research suggesting that cannabis
reduces the experience of pain is in reference to THC, CBD has been associated with
reducing pain that is a result of inflammation (i.e., Boyaji et al., 2020; Burstein, 2015;
Johnson et al., 2010). To the extent that some physiological MRS may be a result of
inflammation, CBD may reduce some physiological symptoms.
In the literature, the effect of CBD on anxiety symptoms is found to be effective
at higher doses (300-600mg), but not lower doses (Bergamaschi et al., 2011; Zuardi et al.,
2017); the current study’s findings are consistent with past literature as we observed
reductions in the 320mg condition, however, we also found reductions in the 160mg
condition (though trends suggest a small dose effect that is consistent with past literature;
see Figure 3). Data also revealed reductions in stress symptoms in both conditions
(showing no dose effect) between baseline and all months of CBD administration.
Further, this study is the first of our knowledge examining the effect of CBD on
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irritability symptoms; findings showed a small reduction in irritability symptoms among
both conditions, in all three cycles of CBD administration when compared to baseline.
Though recent work has suggested that medicinal cannabis may be effective in reducing
depressive symptoms among clinically relevant populations (Martin et al., 2021), current
study findings indicated no impact on depression symptoms (which were generally low in
the current study sample) when comparing all three months of CBD administration to
baseline.
Though CBD has been implicated throughout the literature to increase sleep
quality, we found no impact on sleep quality, however, current study participants
reported good sleep quality at baseline and throughout the study. Recent work has shown
that CBD may function as a neuroprotective factor and treatment for alcohol use (e.g., De
Ternay et al., 2019; Nona et al., 2019; Turna et al., 2019). Further, greater alcohol use is
associated with more severe experiences of MRS (Carroll et al., 2015; Epstein et al.,
2006; Strine et al., 2005). Findings indicated no impact on alcohol use when comparing
all months of CBD administration to baseline; however, we used a homogeneous lowconsuming sample with respect to alcohol use and further research is warranted
investigating the impact of CBD on alcohol use.
There are several strengths of the current study that should be noted. First,
participants consumed CBD for 5 days during each cycle for three consecutive months.
Because of acute dosing (the CBD from the previous month will have already been
largely metabolized), each month can be viewed as a replication. Results showed similar
reductions throughout all months and across all measures. Further, we employed wellvalidated measures to assess MRS and related constructs. Additionally, we used a novel
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dosing paradigm that was a hybrid of acute and chronic dosing. Future work could
examine differences in acute versus prolonged dosing of CBD for the treatment of MRS
as different dosing strategies yields different outcomes. Though the current study’s
findings provide early evidence for the utility of CBD as a treatment for MRS and there
were several strengths, various limitations should be noted. First, we used a relatively
homogenous sample that potentially oversampled individuals who suffer from similar
severity of MRS. Though having a homogenous sample with regards to MRS promotes
reductions of potential confounds, it is possible that CBD may only affect a certain range
of symptom severity; individuals diagnosed with PMDD or who have more severe MRS
may not see the same effect. Future work could examine a range of symptom severity or
clinically relevant samples of individuals who suffer from severe MRS or PMDD to
further assess the utility of CBD as a potential treatment strategy for treating more severe
MRS. Second, the current study relied on individuals self-reporting that they ingested
CBD at prescribed times and doses; we did this to reduce attrition as participants were
enrolled in this study for four consecutive months. Future studies could verify participant
behavior.
Third, the current study did not implement a placebo control. It is possible that the
reductions we see from baseline to all six months of intervention may result from a
placebo effect, as various expectancy effects have been documented on a range of
symptoms that are associated with MRS, such as pain, anxiety, and stress, (e.g., Altman
et al., 2021; De Vita et al., 2021; Spinella et al., 2021). Future work could investigate the
therapeutic efficacy of CBD for MRS using a placebo-controlled trial. Therefore, further
research is warranted examining the utility of CBD in treating MRS as well as the
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potential to optimize CBD administration for reducing MRS (i.e., terpenes, routes of
administration, time of administration). Future work should also investigate the efficacy
of CBD used acutely on days when individuals experience symptoms versus chronically
with respect to MRS.
Further, given that symptom expression of MRS is variable between and among
individuals who experience it, many individuals did not meet criteria for study inclusion
because their cycles did not meet the requirement for a experiencing a regular period
(occurring every 21-38 days). Missing cycles and irregular periods are very common as
many individuals experience stressors or situations that impact the timing of their
menstrual cycle (hormonal imbalance, socioeconomic status, pandemic-related stress;
Kwak et al., 2019; Ozimek et al., 2021). Future research could account for this variability
by using samples that consist of both regular and irregular periods. Last, we did not
validate which cycle phase participants were experiencing at any point of the study, and
further research could investigate the utility of CBD for MRS across different phases of
the menstrual cycle using salivary progesterone concentrations.
Despite limitations, the current study suggests that CBD may be an effective
treatment in alleviating MRS, both physiologically and psychologically. Given the
prevalence of MRS, as well as the relative lack of effective treatments in treating the
entirety of experiences that occur because of MRS, an alternative treatment strategy is
warranted. Taken together, with the findings of the current study, it is reasonable to
consider and further investigate CBD as a viable option for MRS intervention. This study
provides early evidence for CBD as a treatment alternative for MRS and more research is
needed to further determine the utility and to optimize CBD administration for reducing

EFFECTS OF CANNABIDIOL ON MENSTRUAL-RELATED SYMPTOMS

28

MRS with various possibilities for future directions (i.e., with the use of terpenes, using
individuals with more severe MRS, investigating the simultaneous effects of birth control
and CBD).
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Table 1.
Descriptive Statistics of Screener Data
N

M

SD

Min

Max

Age
481 20.52
2.80
18.00 42.00
BMI
576 23.11
3.67
13.35 42.98
Age at Menarche
577 12.53
1.49
7.00 17.00
MRSQ
577 53.59
11.50
26.00 96.00
DASS—Depression
577
8.98
9.27
00.00 42.00
DASS—Anxiety
577
7.12
7.25
00.00 38.00
DASS—Stress
577 11.40
8.34
00.00 42.00
BITE—Total
577 14.44
4.23
5.00 29.00
PSQI Global
577
7.16
3.14
1.00 20.00
DAST Total
577
1.21
1.07
0.00 16.00
AUDIT Total
577
3.89
3.69
0.00 30.00
BITe Total
577 14.44
4.23
5.00 29.00
Subjective Severity Rating
577
2.49
.65
1.00
4.00
Note. 84% Caucasian, 6% Asian American, 3% African American, 2% Middle
Eastern, 5% other; 93% not Hispanic or Latino/x.
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Table 2.
Screener Bivariate Correlations Between MRSQ and Related Constructs
Variable
1
2
3
4
5
6
7
8
1. MRSQ
- .42 .47
.55
.55
.36
.65
.02
2. Depression
.55
.63
.42
.46
.33
.00
3. Anxiety
.72
.36
.35
.35
.06
4. Stress
.54
.45
.38
.01
5. Irritability
.30
.39
.03
6. Sleep
Quality
.22
-.01
7. Subjective
.07
Severity
8. Drug Abuse
9. Alcohol
Use
Note. N = 577.
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9
.10
.14
.09
.13
.09
.10
.02
.21
-
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Table 3.
Participant Screener Descriptive Statistics
M
SD
Min
Max
Age
20.50
2.63
18.00
28.00
BMI
23.09
2.68
19.05
29.68
Age at Menarche
12.48
1.20
10.00
14.00
MRSQ
54.85
12.02
34.00
87.00
DASS—Depression
8.06
6.92
00.00
24.00
DASS—Anxiety
8.00
9.18
00.00
38.00
DASS—Stress
12.67
7.38
2.00
30.00
BITE—Total
14.24
4.23
6.00
27.00
PSQI Global
7.40
3.82
2.00
17.00
DAST Total
1.03
0.92
0.00
4.00
AUDIT Total
3.45
3.27
0.00
11.00
Subjective Severity Rating
2.52
0.51
2.00
3.00
Note. N = 33. 79% Caucasian, 12% Bi-racial; 3% Asian American, 3% Middle
Eastern, 3% other; 93.94% Non-Hispanic or Latino/x.
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Table 4.
Descriptive Statistics of MRS Monthly Health Outcomes
Month
M
SD
MRSQ

Baseline
1
2
3
MRSQ-Physiological Baseline
1
2
3
MRSQ-Psychological Baseline
1
2
3
MRSQ-Appetite
Baseline
1
2
3
Subjective Severity
Baseline
1
2
3
Period Progress
Baseline
1
2
3
Note. N = 33.

51.55
45.00
41.03
41.88
25.82
22.88
21.24
21.55
20.97
18.42
16.09
16.67
4.76
3.70
3.70
3.67
2.70
2.24
2.15
2.09
4.03
3.48
3.03
3.03

10.13
8.37
5.89
7.01
5.90
3.79
3.78
21.55
4.81
5.65
2.82
4.11
1.71
1.29
1.26
1.27
0.59
0.66
0.44
0.72
0.17
0.91
0.85
1.02
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Min

Max

38.00
31.00
31.00
30.00
16.00
16.00
16.00
16.00
12.00
11.00
11.00
11.00
2.00
2.00
2.00
2.00
2.00
1.00
1.00
1.00
4.00
2.00
1.00
1.00

85.00
72.00
56.00
59.00
46.00
33.00
32.00
29.00
31.00
33.00
22.00
28.00
8.00
6.00
7.00
6.00
4.00
4.00
4.00
4.00
5.00
5.00
5.00
5.00
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Table 5.
Descriptive Statistics of Other Monthly Health Outcomes
Month
M
DASS-Anxiety

DASS-Depression

DASS-Stress

BITe

PSQI

AUDIT

VAMS

Note. N = 33.

Baseline
1
2
3
Baseline
1
2
3
Baseline
1
2
3
Baseline
1
2
3
Baseline
1
2
3
Baseline
1
2
3
Baseline
1
2
3

8.61
5.40
6.49
6.00
8.85
6.06
6.61
7.94
12.67
10.12
9.88
8.61
13.48
11.73
11.79
11.58
5.94
5.36
5.97
5.70
4.15
3.70
3.97
3.73
26.27
26.61
26.88
27.03
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SD

Min

Max

6.72
5.23
5.55
6.52
6.65
5.37
6.60
7.94
7.74
6.78
6.58
6.31
4.14
3.44
3.39
3.49
3.61
3.19
2.82
2.94
3.47
3.02
3.67
3.24
18.27
16.71
20.53
18.58

0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
7.00
6.00
5.00
5.00
1.00
1.00
2.00
2.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00

24.00
20.00
20.00
28.00
20.00
20.00
24.00
32.00
28.00
30.00
24.00
24.00
23.00
20.00
19.00
19.00
17.00
14.00
13.00
13.00
10.00
9.00
13.00
12.00
83.00
78.00
87.00
82.00
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Figures
Figure 1.
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Figure 2.
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Figure 3.
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Figure 4.
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Figure 5.
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Figure 6.
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Figure 7.
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